Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Stage III Prostate Cancer: early-phase trial registry

A small indexed set (10 trials) with no open enrollment listed right now.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count

Stage III Prostate Cancer: 10 US clinical trials tracked, none currently recruiting.

Stage III Prostate Cancer is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition stage-iii-prostate-cancer

OPEN 0 | RECR 0% | LATE 0 | EARLY 6 | RANK #1724 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Stage III Prostate Cance (th…0%
Open-enrollment share among volume-matched conditions near Stage III Prostate Cancer

Stage III Prostate Cancer has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage III Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage III Prostate Cancer is recruiting below its size-band peers.

    0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Stage III Prostate Cancer trials is spread across many organizations.

    Jonsson Comprehensive Cancer Center accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage III Prostate Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 49 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Stage III Prostate Cancer research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING NA 220 participants

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT02296229

ACTIVE NOT RECRUITING NA 146 participants

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Stanford University

NCT02346253

ACTIVE NOT RECRUITING Phase 1 56 participants

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

Ohio State University Comprehensive Cancer Center

NCT01823562

ACTIVE NOT RECRUITING NA 33 participants

Researching the Effect of Exercise on Cancer

Memorial Sloan Kettering Cancer Center

NCT04589468

ACTIVE NOT RECRUITING Phase 1 26 participants

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

City of Hope Medical Center

NCT01923506

ACTIVE NOT RECRUITING Phase 1 25 participants

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Thomas Jefferson University

NCT02023463

COMPLETED Phase 2 112 participants

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Mayo Clinic

NCT00170157

COMPLETED Phase 2 49 participants

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

National Cancer Institute (NCI)

NCT00103194

COMPLETED NA 30 participants

Visually Enhanced Education About Prostate Cancer

Vanderbilt-Ingram Cancer Center

NCT02846870

COMPLETED Phase 2 5 participants

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

University of Washington

NCT00466752

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Named interventions

Most-linked intervention names on Stage III Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

laboratory biomarker analysis Other
4 trials
quality-of-life assessment Procedure
2 trials
stereotactic body radiation therapy Radiation
2 trials
Leuprolide Acetate Drug
2 trials
Goserelin Acetate Drug
2 trials
Bicalutamide Drug
2 trials
needle biopsy Procedure
1 trials
Standard prostate cancer education presentation Other
1 trials

US sites by state

Facility locations filed on Stage III Prostate Cancer trials. A trial with sites in several states counts in each.

California 4 trials
Pennsylvania 2 trials
Washington 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage III Prostate Cancer page

10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Stage III Prostate Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Jonsson Comprehensive Cancer Center sponsors the most Stage III Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Prostate Cancer condition card totals 10 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.